On Dec 8, 2018 Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Shorts Rose By 7.64%

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Corporate Logo

Big Money Sentiment increased to 1.38 in Q2 2018. It has change of 0.43, from 2018Q1’s 0.95. The ratio is positive due to Achillion Pharmaceuticals, Inc. positioning: 11 sold and 29 reduced. 16 funds bought positions and 39 increased positions. Investors holded 107.48 million in 2018Q1 but now own 105.68 million shares or 1.67% less.
Amer International stated it has 88,582 shs or 0% of all its holdings. Northern Trust Corporation invested in 1.61M shs. Amalgamated Retail Bank has 18,270 shs. Balyasny Asset Mngmt Limited Liability owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 60,234 shs. Renaissance Lc reported 875,899 shs. Teton Inc reported 10,000 shs. Td Asset Mngmt holds 0% or 205,487 shs. Piedmont Invest Advisors Ltd Liability Co holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 2,361 shs. Susquehanna Intl Group Incorporated Llp invested in 0% or 134,041 shs. Spark Invest Mngmt Limited Liability Com accumulated 195,900 shs or 0.03% of the stock. Blackrock reported 11.86M shs stake. 102,307 are held by Connor Clark & Lunn Inv Mgmt Ltd. Tiaa Cref Limited Liability Corporation reported 621,860 shs. Barclays Public Limited has invested 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Panagora Asset Mngmt holds 0.01% or 1.24M shs.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) had an increase of its shorted shares by 7.64%. It was issued in December by FINRA the 6.14 million shorted shares on ACHN. That’s 7.64% up from 5.70M shares. Former ACHN’s position will need 5 days to restore. It has 1.30 million average volume. Achillion Pharmaceuticals Inc’s shorted shares float is 4.92%.

The stock decreased 0.64% or $0.02 during the last trading session, hitting $3.11.Achillion Pharmaceuticals, Inc. has volume of 1.20M shares. Since December 8, 2017 ACHN has declined 11.53% and is downtrending. ACHN underperformed by 27.15% the S&P500.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.The firm is valued at $431.10 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial.Last it reported negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

For more Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Zacks.com. The titles are as follows: “Achillion Is A Worthwhile Biotech Speculation – Seeking Alpha” published on July 12, 2018, “FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US – Seeking Alpha” on August 20, 2018, “Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer – GlobeNewswire” with a publish date: August 15, 2018, “Achillion Reports First Quarter 2018 Financial Results and Management Transition – GlobeNewswire” and the last “Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue? – Zacks.com” with publication date: August 31, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.